BioSpace News Archive

Bio-Path Holdings, Inc. announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 375,000 shares of its common stock at a purchase price of $3.225 per share and concurrent private placement of unregistered warrants to purchase up to an aggregate of 375,000 shares of common stock.

The global liquid biopsy market size was valued at USD 10.85 billion in 2023 and is projected to reach USD 32.54 billion by 2033, growing at a CAGR of 11.61% from 2024 to 2033 according to a new report by Nova One Advisor.

Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Matthijs Glastra, Chair & Chief Executive Officer, and Robert Buckley, Chief Financial Officer, are scheduled to present at the William Blair 44th Annual Growth Stock Conference on Tuesday, June 4, 2024, in Chicago, IL.

Soleno Therapeutics, Inc. announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to six new employees.

NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”) is pleased to announce that Dr. Lior Shaltiel, CEO and Director at NurExone, was invited to present on “Revolutionizing Spinal Cord Injury Treatment: Harnessing the Potential of Exosomes for Advanced Therapy in Comprehensive Approach” at the Exosomes of Europe conference in London in June, 2024.

Calidi Biotherapeutics, Inc. announced the closing of its previously announced public offering of 15,197,500 shares of common stock and accompanying Series A Common Warrants, Series B Unit Warrants, with each unit consisting of one share of common stock and a Series B-1 Common Warrant and Series C Unit Warrants.

Acadia Pharmaceuticals Inc. announced that on April 10, 2024, the Compensation Committee of Acadia’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 21,659 shares of common stock and 12,739 restricted stock units to six new employees under Acadia’s 2023 Inducement Plan.

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) today announced that it has begun wind-down activities in its ASCEND-NASH Trial, while continuing to explore strategic alternatives, as previously announced in December 2023.

ASLAN Pharmaceuticals announced that it received a letter on April 18, 2024 from The Nasdaq Stock Market informing the Company that it failed to maintain the continued listing requirement under Nasdaq Listing Rule 5550 for the Nasdaq Capital Market, which requires that a listed company’s stockholders’ equity be at least $2.5 million.

Iovance Biotherapeutics, Inc. announced that on April 18, 2024, the Company approved the grant of inducement stock options covering an aggregate of 79,310 shares of Iovance’s common stock to thirty-seven new, non-executive employees.